ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation: Executive Summary A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the North American Society of Pacing and Electrophysiology.
Fuster
V
V
Rydén
L E
LE
Asinger
R W
RW
Cannom
D S
DS
Crijns
H J
HJ
Frye
R L
RL
Halperin
J L
JL
Kay
G N
GN
Klein
W W
WW
Lévy
S
S
McNamara
R L
RL
Prystowsky
E N
EN
Wann
L S
LS
Wyse
D G
DG
Gibbons
R J
RJ
Antman
E M
EM
Alpert
J S
JS
Faxon
D P
DP
Fuster
V
V
Gregoratos
G
G
Hiratzka
L F
LF
Jacobs
A K
AK
Russell
R O
RO
Smith
S C
SC
Klein
W W
WW
Alonso-Garcia
A
A
Blomström-Lundqvist
C
C
de Backer
G
G
Flather
M
M
Hradec
J
J
Oto
A
A
Parkhomenko
A
A
Silber
S
S
Torbicki
A
A
D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000145:classification / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D001282:Atrial Flutter / Q000175:diagnosis; D015897:Comorbidity; D003937:Diagnosis, Differential; D019468:Disease Management; D004554:Electric Countershock; D004562:Electrocardiography; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D015995:Prevalence; D011379:Prognosis; D044469:Racial Groups; D018570:Risk Assessment; D013610:Tachycardia / Q000175:diagnosis; D013923:Thromboembolism / Q000209:etiology / Q000517:prevention & control
D000889:Anti-Arrhythmia Agents; D005343:Fibrinolytic Agents